Trade Mark Journal No.2026/026 26 June 2026

WO0000001922072 (5)

Office of origin: United States of America

Date of International Registration:17 April 2026
Date of designation in the UK: 17 April 2026
Image for mark 1922072 NEUPLIXO

International priority date claimed: 26 February 2026 (Tonga)
Class 5
Pharmaceutical preparations for the treatment of mental health conditions; pharmaceutical preparations, namely, psychotropic, psychoactive, and psychedelic medicinal preparations for the treatment of mental health conditions; pharmaceutical preparations for the treatment of psychiatric diseases and disorders, namely, generalized anxiety disorder (gad) and major depressive disorder (mdd).

Definium Therapeutics US, Inc.

Representative: John Paul Oleksiuk Cooley LLP, 1299 Pennsylvania Ave. NW STE 700, Washington DC 20004, UNITED STATES OF AMERICA